NCT06206330 is a NA clinical trial of Platelet rich plasma in Pilonidal Disease, sponsored by İsmail Oskay Kaya.

Who is sponsoring NCT06206330?

NCT06206330 is sponsored by İsmail Oskay Kaya.

What drugs are being tested in NCT06206330?

Interventions in NCT06206330: Platelet rich plasma.

What condition does NCT06206330 study?

NCT06206330 studies Pilonidal Disease, Pilonidal Sinus.

Is NCT06206330 still recruiting?

NCT06206330 is currently completed. Last updated 16 January 2024.

Last reviewed 2024-01-16 · How we verify

NCT06206330

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Platelet Rich Plasma (PRP) on Healing Time in Patients Following Pilonidal Sinus Surgery

Completed NA Last updated 16 January 2024

What this trial tests

NA trial testing Platelet rich plasma in Pilonidal Disease in 140 participants. Completed in 1 November 2022.

Timeline

1 November 2021

Primary endpoint
1 November 2022

1 November 2022

Quick facts

Lead sponsor	İsmail Oskay Kaya
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	140
Start date	1 November 2021
Primary completion	1 November 2022
Estimated completion	1 November 2022
Sites	1 location across Turkey (Türkiye)

Drugs / interventions tested

Platelet rich plasma — full drug profile →

Conditions studied

Pilonidal Disease — all drugs for Pilonidal Disease →
Pilonidal Sinus — all drugs for Pilonidal Sinus →

Sponsor

İsmail Oskay Kaya

Who can join

Adults 18 to 59, any sex, with Pilonidal Disease or Pilonidal Sinus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Our study was planned as a prospective controlled randomized study. The study was started after the ethics committee approval received from Dışkapı Yıldırım Beyazıt Training and Research Hospital. (23.08.2021 118/01). Two groups of patients were planned in parallel. In the treatment of pilonidal sinus disease, in patients operated on with the fistulotomy and curettage technique, one group was followed up with classical dressing, while the other group was followed up with PRP (platelet-rich-plasma) and classical dressing. Wound infection, hematoma, length of hospital stay, recurrence, pain in the first postoperative week, and time to complete epithelialization of the wound (in days) were evaluated between the two groups.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

The power of platelet-rich plasma on operated pilonidal disease: a prospective randomized controlled trial.
Chousein B, Olcucuoglu E, Kaya IO. · · 2025 · PMID 39944926 · DOI 10.4174/astr.2025.108.2.124

Verify or expand the search:

Other trials of Platelet rich plasma

Trials testing the same drug.

NCT06510673 — Extracorporeal Shock Wave Therapy Versus High Power LASER Therapy for the Treatment of Females With Calcaneal Spur · NA · not yet recruiting
NCT06532318 — Comparative Study Between Platelet Rich Plasma and Steroid Injection in Trigger Finger Treatment · Phase 3 · not yet recruiting
NCT06814535 — A Comparative Study on the Impact of Trigger Points Injection of Platelet Rich Plasma Versus Botulinum Toxin on the Reli · Phase 2, PHASE3 · active not recruiting
NCT06440655 — The Efficacy and Safety of Platelet-rich Fibrin and Platelet Rich Plasma in Female Pattern Hair Loss Patients · NA · recruiting
NCT05479474 — Platelet Rich Plasma Testis Treatment for Infertile Men · NA · recruiting

Other recruiting trials for Pilonidal Disease

Currently open trials in the same condition.

NCT07321704 — Effect of Antiseptic Irrigations With 0.05% Chlorhexidine Gluconate (Irrisept) Versus Normal Saline on Fasciocutaneous F · NA · recruiting
NCT06406621 — Pilot Trial Assessing the Effectiveness of Laser Hair Depilation on Pilonidal Disease Recurrence in Patients With Darker · NA · recruiting
NCT06286397 — Topical Anti-Androgens in Pilonidal Sinus Disease · Phase 2 · recruiting
NCT06391307 — The Role of Mesenchymal Stem Cell and Exosome in Treating Pilonidal Sinus Disease in Children · NA · recruiting
NCT03772873 — MIPE for Pilonidal Disease · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06206330 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by İsmail Oskay Kaya
Last refreshed: 16 January 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06206330.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing